Company intelligence / Profile preview

Well Cell Global

Houston, Texas, United Stateswellcellglobal.com ↗

Ownership: Private
Development stage: Commercial

Overview

Well Cell Global provides a patented approach called Physiologic Insulin Resensitization where insulin is administered as a hormone rather than a drug to address metabolic failure. The treatment has been written about in eight peer-reviewed published medical journal articles[7].

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Insulin-based treatment
Industry: Biotech

Drug pipeline

1 asset

PIR

Commercial

Indications: Diabetes, Metabolic disorders, Insulin resistance

Partnerships

University at Buffalo's Center for Integrated Global Biomedical Sciences[3][5]

Beyond the preview

Go deeper on Well Cell Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Well Cell Global.

Explore the full profile